ESMO: Agios celebrates milestone win for ivosidenib in tough-to-treat bile duct cancer

For Agios, just running a global phase 3 trial in a tough-to-treat bile duct cancer was a major milestone. The fact that it came up positive has the company over the moon. Monday, Agios touted results showing its ivosidenib—also known as Tibsovo—could benefit patients with advanced cholangiocarcinoma.